
<div id="title">SPIRIVA: The most prescribed COPD therapy in Australia and worldwide<little>1</little></div>
<div class="study-design-icon sd-show-panel">
    <img alt="Study design icon" height="46" id="icon" src="assets/study-design-icon-8772e4ea8aec804660af66a10186ee81.png" width="46">
    <p>UPLIFT</p>
</div>
<div id="chart">
	<ul class="row-1">
		<li class="list-1"></li>
		<li class="list-2">Dry powder inhaler</li>
		<li class="list-3">Once daily dosing</li>
		<li class="list-4">Indicated for prevention of COPD exacerbations</li>
		<li class="list-5">Proven to reduce mortality<sup>5–7</sup></li>
		<li class="list-6">‘Very severe’ COPD patients included in phase III program<sup>5,8</sup></li>
		<li class="list-7">Longest trial duration<sup>†</sup></li>
		<li class="list-8">Minimum flow rate required<br/>(L/min)<sup>9</sup></li>
		<li class="list-9">Dissociation half-life from M<sub>3</sub> receptor (hours)<sup>10</sup></li>
	</ul>
	<ul class="row-2">
		<li class="list-1" id="button-spiriva">SPIRIVA<sup>2</sup> HandiHaler</li>
		<li class="list-2"></li>
		<li class="list-3"></li>
		<li class="list-4"></li>
		<li class="list-5"><span>‡</span></li>
		<li class="list-6"></li>
		<li class="list-7">4 years</li>
		<li class="list-8">38.8</li>
		<li class="list-9">27</li>
	</ul>
	<ul class="row-3">
		<li class="list-1" id="button-bretaris">Bretaris<sup>®</sup> Genuair<sup>®</sup><p style="font-size:13px;margin: 0;">(aclidinium bromide)<sup>3</sup></p></li> 
		<li class="list-2"></li>
		<li class="list-3"></li>
		<li class="list-4"></li>
		<li class="list-5"></li>
		<li class="list-6"></li>
		<li class="list-7">24 weeks</li>
		<li class="list-8">64.5</li>
		<li class="list-9">10.7</li>
	</ul>
	<ul class="row-4">
		<li class="list-1" id="button-seebri">Seebri<sup>®</sup> Breezhaler<sup>®</sup><p style="font-size:13px;margin: 0;">(glycopyrronium bromide)<sup>4</sup></p></li>
		<li class="list-2"></li>
		<li class="list-3"></li>
		<li class="list-4"></li>
		<li class="list-5"></li>
		<li class="list-6"></li>
		<li class="list-7">1 year</li>
		<li class="list-8">105.3</li>
		<li class="list-9">6.1</li>
	</ul>
</div>
<div id="lit-logo"></div>
<div id="text">
	<p><sup>†</sup>Increases time to first exacerbation</p>
    <p>vs placebo, salmeterol and indacaterol<sup>2,11</sup></p>
</div>
<div id="text2">
    <p class="text-b"><sup>†</sup>As listed in the current Australian Approved Product Information.<sup>2–4</sup></p>
    <p class="text-b"><sup>‡</sup>Reduction of mortality risk vs placebo (4-year on-treatment and ITT</p>
    <p class="text-b">analysis both p&lsaquo;0.05). 4-year + 30-day follow-up ITT p=not significant.<sup>6,7</sup></p>
    <p class="text-b"><sup>§</sup>No data available as of September 2014.</p>
    <br/>
    <p>Bretaris<sup>®</sup> Genuair<sup>®</sup> is a registered trademark of A. Menarini Australia Pty Ltd.</p>
    <p>Seebri<sup>®</sup> Breezhaler<sup>®</sup> is a registered trademark of Novartis Pharmaceuticals Australia Pty Ltd.</p>
</div>